TORONTO A year into the pandemic and sick of being cooped up in their homes, many Canadians may feel like theyâre near the breaking point. But for infants and toddlers, the lack of contact with people outside of their immediate family means theyâre missing out on social and biological interactions that are key for their development, say experts. Marie-Claire Arrieta, an assistant professor in the department of physiology and pharmacology at the University of Calgaryâs Cumming School of Medicine, says that the early years up until pre-school age are critical for exposure to microorganisms that help digest our food, protect us from disease and regulate our immune system.
Study: Longer time to stroke treatment increases risk for longer recovery upi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from upi.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of .
Arch BiopartnersFebruary 26, 2021 GMT
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Peter Lougheed Center (PLC) in Calgary, Alberta has joined the Phase II trial of its lead drug LSALT peptide (Metablok), targeting the prevention of acute lung injury, acute kidney injury, and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.
Here s when experts say Canadian kids will get the COVID-19 vaccine todaysparent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from todaysparent.com Daily Mail and Mail on Sunday newspapers.
Author of the article: Jason Herring
Publishing date: Feb 13, 2021 • February 13, 2021 • 3 minute read • Dr. Dan Muruve (left), chief science officer of Arch Biopartners, and Dr. Alain Tremblay, professor at the University of Calgary s Cumming School of Medicine, are facilitating a Phase II human trial in Calgary for Metablok, a drug developed to combat organ inflammation often in severe cases of COVID-19. Photo by Submited
Article content
A made-in-Calgary drug that researchers hope can treat organ inflammation is now being tested on local COVID-19 patients.
The University of Calgary has joined a Phase II human trial of Metablok, a novel drug developed to combat inflammation of the lungs, kidneys and other organs complications often seen in those with moderate to severe cases infections of the novel coronavirus.